Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results
1. EW reported adjusted earnings of 67 cents, exceeding estimates. 2. Quarterly sales hit $1.532 billion, above the expected $1.488 billion. 3. FY2025 EPS guidance was affirmed at $2.40-$2.50. 4. Sales guidance for FY2025 increased to $5.90-$6.10 billion. 5. Analysts raised their price targets following the earnings announcement.